Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
AbbVie is a research-based biopharmaceutical company with a portfolio anchored by Humira (immunology), Skyrizi/Rinvoq (next-generation immunology), Imbruvica (oncology), and the Allergan Aesthetics franchise (Botox, fillers). The company faces Humira biosimilar erosion in the U.S. (began 2023) but is offsetting this with rapid growth in Skyrizi/Rinvoq, which are expected to exceed $27B in combined sales by 2027. Stock performance hinges on the pace of new immunology asset adoption and successful pipeline execution in neuroscience and oncology.
AbbVie operates a patent-protected specialty pharmaceutical model with high gross margins (83.7%) driven by biologics and branded drugs. Pricing power stems from clinical differentiation in chronic conditions (psoriasis, rheumatoid arthritis, Crohn's disease) where switching costs are high and physician relationships matter. The company invests heavily in R&D (approximately $7B annually) to maintain pipeline flow, with recent focus on immunology line extensions, oncology combinations, and neuroscience. Humira biosimilar competition (U.S. market lost exclusivity January 2023) is being offset by Skyrizi/Rinvoq, which demonstrate superior efficacy profiles and are gaining formulary access. Aesthetics provides counter-cyclical diversification with recurring revenue from repeat procedures.
Skyrizi/Rinvoq combined revenue growth rate and market share gains in immunology (targeting $27B+ by 2027)
Pace of Humira U.S. biosimilar erosion and international sales retention
Pipeline readouts in neuroscience (schizophrenia, Alzheimer's) and oncology (solid tumors)
Aesthetics revenue trends reflecting consumer discretionary spending on elective procedures
M&A activity and capital deployment (company has history of large acquisitions like Allergan for $63B in 2020)
Biosimilar competition expanding beyond Humira to other biologics, compressing pricing power across the industry
Drug pricing reform including Medicare negotiation (IRA implementation) and potential international reference pricing reducing revenue per patient
Patent cliffs on key assets (Imbruvica faces generic competition in 2027, Skyrizi/Rinvoq patents expire early 2030s)
FDA safety concerns on JAK inhibitors (Rinvoq carries black box warning for serious cardiovascular events, malignancies) limiting prescribing
Johnson & Johnson's Tremfya and Eli Lilly's Taltz competing in immunology with similar efficacy profiles
Emerging oral immunology therapies (TYK2 inhibitors from BMS, Sanofi) potentially disrupting injectable biologic market
Aesthetics competition from Evolus (Jeuveau) and Revance (Daxxify) in neurotoxin market, plus increasing use of GLP-1 agonists reducing demand for cosmetic procedures
Elevated debt-to-equity ratio (-26.02 due to negative equity from Allergan acquisition accounting) with $93B gross debt requiring disciplined cash flow management
Pension and post-retirement benefit obligations (approximately $3B underfunded) creating long-term liabilities
Contingent liabilities from litigation (opioid settlements, talc-related claims from Allergan legacy) though most major settlements resolved
low - Prescription pharmaceutical demand is largely non-discretionary and driven by disease prevalence rather than GDP. However, Aesthetics segment (12-15% of revenue) is highly cyclical as Botox and filler procedures are elective and correlate with consumer confidence and discretionary spending. Immunology and oncology revenues remain stable through recessions.
Rising rates increase debt service costs on AbbVie's $93B debt load (legacy from Allergan acquisition), though the company generates strong operating cash flow ($20B+ annually) to service obligations. Higher rates also compress valuation multiples for dividend-paying biopharma stocks, as AbbVie's 3.5% yield becomes less attractive versus risk-free alternatives. Refinancing risk is manageable with staggered maturities.
Minimal direct exposure. Pharmaceutical reimbursement is primarily through government programs (Medicare Part D, Medicaid) and commercial insurers with stable payment terms. Patient affordability programs and copay assistance insulate demand from credit tightening, though severe recessions could pressure state Medicaid budgets.
dividend - AbbVie offers a 3.5% dividend yield with 52 consecutive years of increases (Dividend Aristocrat status), attracting income-focused investors. Also appeals to value investors during patent transition periods when stock trades at discounted multiples (current 16.7x EV/EBITDA below historical average). Growth investors focus on Skyrizi/Rinvoq trajectory offsetting Humira decline.
moderate - Beta typically 0.6-0.8 reflecting defensive healthcare characteristics, but stock experiences volatility around pipeline readouts, FDA decisions on safety labels, and quarterly earnings when Humira erosion pace is assessed. Aesthetics exposure adds modest cyclical sensitivity.
